T-DXd has been approved for the treatment of metastatic HER2-positive and -low breast cancer, metastatic HER2-positive gastric cancer, and metastatic HER2-mutant non-small cell lung cancer in many countries, including (but not limited to) the United States, Japan, and Europe [15–17]. The gene discussed is ERBB2; the disease is breast carcinoma.